Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients

Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients

AZD7442 (tixagevimab-cilgavimab) is a combination of two human monoclonal antibodies for pre-exposure prophylaxis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among high-risk patients who do not mount a reliable vaccine response. Foremost among these are hematologic mal...

Full description

Bibliographic Details
Main Authors: Justin C. Laracy, Judy Yan, Samantha N. Steiger, Carrie A. Tan, Nina Cohen, Elizabeth V. Robilotti, Jerome Fender, Sara Cohen, Neha Korde, Melissa Lee-Teh, Ariela Noy, Joseph H. Oved, Lindsey E. Roeker, Gunjan Shah, N. Esther Babady, Mini Kamboj, Susan K. Seo
Format: Article
Language:English
Published: Ferrata Storti Foundation 2023-06-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/11128

Internet

https://haematologica.org/article/view/11128

Similar Items